Bender Robert & Associates Biocryst Pharmaceuticals Inc Transaction History
Bender Robert & Associates
- $414 Million
- Q4 2024
A detailed history of Bender Robert & Associates transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Bender Robert & Associates holds 23,710 shares of BCRX stock, worth $206,751. This represents 0.04% of its overall portfolio holdings.
Number of Shares
23,710Holding current value
$206,751% of portfolio
0.04%Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
285Shares Held
171MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$177 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$174 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$103 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$79.2 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$77.2 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.62B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...